Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolization

Yi, Sun Woo; Kim, Yong Hee; Kwon, Ick Chan; Chung, Jin Wook; Park, Jae Hyung; Choi, Young Wook; Jeong, Seo Young

doi:10.1016/s0168-3659(97)00127-2

Cited by 35 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The thermodynamical stability of LIPDOX emulsions can be improved by the addition of densifiers (substances that increase the density of the aqueous phase) and emulsifiers [67]. When the density of the aqueous phase was increased to bring it closer to that of LIP (1.28 g/cm 3 ), the stability period for LIPDOX w/o emulsions was increased from 3-24 h [69].…”

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

“…Various densifiers, such as 60% diatrizoate sodium meglumine (Urografin ® ), iohexol (Omnipaque 300™), or iopamidol, have been used in LIPDOX formulations [52,63,67,69]. Various emulsifiers with different degrees of hydrophilic-lipophilic balance (HLB) have also been tested for their ability to improve LIPDOX emulsion stability.…”

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

“…Various emulsifiers with different degrees of hydrophilic-lipophilic balance (HLB) have also been tested for their ability to improve LIPDOX emulsion stability. Hydrogenated castor oil 60 (HCO-60, HLB 14-15) and Pluronic F68 (HLB 29) have been used for this purpose [63,[66][67]70]. As shown in Figure 4, release of DOX from LIPDOX w/o emulsions stabilized with emulsifiers and/or densifiers was slower in vitro than that from the unstabilized LIPDOX w/o emulsion.…”

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

“…In general, w/o/w emulsions are unstable and immediate release from LIPDOX w/o/w emulsions has been reported [67,71]. However, some published sustained-release profiles indicate that LIPDOX w/o/w emulsions can be stabilized [66].…”

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

“…Two main mixing procedures have been described: homogenization by ultrasonic bath or homogenizer and an extemporaneous pumping technique where two connected syringes (one containing an aqueous solution of DOX and one containing LIP) are used to emulsify the two phases by pumping the syringes until an emulsion is formed [52,67]. The preparation technique chosen will probably influence both the in vitro and the in vivo release of DOX from the emulsion, as the intensity of mixing influences the droplet size of the inner phase, irrespective of whether the inner phase is aqueous or LIP.…”

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

See 4 more Smart Citations

Treatment of Intermediate Stage Hepatocellular Carcinoma: A Review of Intrahepatic Doxorubicin Drug-Delivery Systems

Dubbelboer

Lilienberg

Ahnfelt

et al. 2014

Therapeutic Delivery

View full text Add to dashboard Cite

The biopharmaceutical properties of doxorubicin delivered via two drug-delivery systems (DDSs) for the palliative treatment of unresectable hepatocellular carcinoma were reviewed with relation to the associated liver and tumor (patho)physiology. These two DDSs, doxorubicin emulsified with Lipiodol ® and doxorubicin loaded into DC Bead ® are different regarding tumor delivery, release rate, local bioavailability, if and how they can be given repeatedly, biodegradability, length of embolization and safety profile. There have been few direct head-to-head comparisons of these DDSs, and in-depth investigations into their in vitro and in vivo performance is warranted.The global incidence of liver cancer is increasing and this type of cancer has a poor prognosis and is ranked as the third most common lethal cancer form [1,2]. The recommended treatment for hepatocellular carcinoma (HCC), a primary liver cancer, is dependent on the stage of the disease [3]. For unresectable, intermediate stage HCC, transarterial chemoembolization (TACE) is recommended. TACE involves the delivery of the cytostatic agent(s) in a drug-delivery system (DDS) to the tumor via the hepatic artery (HA) [3]. In contrast to normal liver tissue, which has a dual blood supply from the HA and the portal vein [4], HCC is typically mainly vascularized by the HA. Local drug administration by the TACE DDS is expected to increase the specificity of the tumor response while reducing the frequency of side effects and morbidity compared with systemic dosed treatments [4]. Embolization, caused by the DDS, obstructs the blood flow in the tumor, induces hypoxia, and results in increased drug concentrations and prolonged residence times in the tumortarget area [4]. Patients with untreated HCC that has not invaded the portal vein or spread extrahepatically have an expected median survival of approximately 16 months. With current palliative TACE strategies, the expected median survival is prolonged by approximately 4 months [3].To date, several DDSs delivering various chemotherapeutic drug(s) and pharmaceutical excipients have been developed and clinically evaluated for TACE therapy [5]. A review of these options of TACE DDSs is warranted in that it would form the basis for optimizing tumor-targeted therapy for HCC treatment, and subsequent development of novel, tumor-targeted DDSs and dosing strategies. Two common DDSs used for TACE therapy for intermediate stage HCC involve cytostatic agents emulsified in Lipiodol ® (LIP) or loaded into drugeluting beads. LIP is an iodized poppy seed oil derivative visible on x-ray, and after administration, the contrast is preferentially retained in tumor tissue [6,7]. The combination of the cytostatic agent emulsified in LIP can be administered with or without additional embolizing materials, generating complete or partial embolization of the targeted tumor-feeding vessel(s) [3,8]. DC Bead ® (DCB) is one of several commercially available drug-eluting embolizing bead systems [9]. Positively charged chemotherapeutic drugs can be ...

show abstract

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

Section: Release Of Dox From Lipdox In Vitromentioning

confidence: 99%

See 3 more Smart Citations

Treatment of Intermediate Stage Hepatocellular Carcinoma: A Review of Intrahepatic Doxorubicin Drug-Delivery Systems

Dubbelboer

Lilienberg

Ahnfelt

et al. 2014

Therapeutic Delivery

View full text Add to dashboard Cite

show abstract

A Lipiodol Pickering Emulsion Stabilized by Iron‐Doped Carbon Nanozymes for Liver Transarterial Chemoembolization

Xia,

Li,

Huang

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) utilizing a water‐in‐oil lipiodol emulsion is a preferable therapeutic strategy for advanced liver cancer in clinical practice. However, the low stability of the lipiodol emulsion and poor efficacy of chemotherapeutic drug seriously undermine the efficiency of TACE. Herein, a novel lobaplatin‐loaded lipiodol emulsion (denoted as ICN‐LPE) is developed by constructing a lipiodol Pickering emulsion (LPE) stabilized with iron‐doped carbon nanozymes (ICN) to mitigate the issue of lipiodol‐water separation. This novel emulsion not only solves the instability of conventional lipiodol emulsions, but also facilitates the sustained release of lobaplatin. More importantly, upon entry into tumor cells, ICN catalyze the generation of reactive oxygen species via the Fenton‐like reaction while simultaneously consuming intracellular glutathione, thereby inducing tumor cell death via chemodynamic therapy. By integrating chemotherapy and chemodynamic therapy, ICN‐LPE demonstrates a synergistic antitumor effect and effectively inhibits tumor growth in a rabbit liver tumor model. Therefore, our ICN‐LPE shows an appealing clinical application prospect for TACE.

show abstract

Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis

Falk¹,

Gross²,

Guillevin³

et al. 2011

Arthritis & Rheumatism

263

View full text Add to dashboard Cite

Williams syndrome (WS), caused by hemizygous deletion of 1.55–1.8 Mb of chromosome 7q11.23, has a recognizable behavior phenotype that is an important diagnostic sign. Individuals with WS are overly friendly, gregarious, empathetic, and loquacious, but have difficulty interpreting social cues and in making and keeping friends. The neurodevelopmental profile is characterized by overall intellectual disability, strength in concrete language, weakness in visuospatial construction, difficulties with sensory modulation, balance, and tool use, and problems with attention and anxiety. Structural and functional MRI studies demonstrate that gray matter deficiency in the intraparietal sulcus alters processing of spatial information in the dorsal stream (spatial) visual pathway, likely contributing to the visuospatial construction disability. Deficient regulation of the amygdala by the oribitofrontal cortex appears to underlie both the social disinhibition and the specific phobia common in WS. Continued study of cognition, behavior, neuroanatomy, and function in WS will continue to elucidate the neurogenetic underpinnings of human behavior. © 2010 Wiley‐Liss, Inc.

show abstract

Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolization

Cited by 35 publications

References 23 publications

Treatment of Intermediate Stage Hepatocellular Carcinoma: A Review of Intrahepatic Doxorubicin Drug-Delivery Systems

Treatment of Intermediate Stage Hepatocellular Carcinoma: A Review of Intrahepatic Doxorubicin Drug-Delivery Systems

A Lipiodol Pickering Emulsion Stabilized by Iron‐Doped Carbon Nanozymes for Liver Transarterial Chemoembolization

Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis

Contact Info

Product

Resources

About